Third win for cannabis drug in epilepsy sends GW to record high
An experimental cannabis-derived drug has successfully treated children with severe epilepsy in a third late-stage clinical trial, sending shares in Britain's GW Pharmaceuticals to a record high on Monday. GW, which was founded in 1998 to capitalize on the medical benefits of cannabis, said it now...